Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13117571 | 0.92 | DGAT1 (0.43) | EPHX2DGAT1FAAHGCGRRAF1 | |
| SCHEMBL10184422 | 0.90 | EPHX2 (0.42) | EPHX2DGAT1FAAHGCGRHRH3 | |
| SCHEMBL10185063 | 0.88 | EPHX2 (0.48) | EPHX2DGAT1FAAHGCGRRAF1 | |
| SCHEMBL10185174 | 0.88 | DGAT1 (0.46) | EPHX2DGAT1FAAHL3MBTL1HRH3 | |
| SCHEMBL10185275 | 0.87 | EPHX2 (0.53) | EPHX2DGAT1FAAHGCGRRAF1 | |
| SCHEMBL10185089 | 0.87 | DGAT1 (0.47) | EPHX2DGAT1FAAHL3MBTL1HRH3 | |
| SCHEMBL10185419 | 0.87 | FAAH (0.48) | EPHX2DGAT1FAAHGCGRRAF1 | |
| SCHEMBL13117516 | 0.86 | DGAT1 (0.47) | EPHX2DGAT1FAAHGCGRRAF1 | |
| SCHEMBL10186486 | 0.85 | EPHX2 (0.44) | EPHX2DGAT1FAAHGCGRRAF1 | |
| SCHEMBL10186415 | 0.85 | EPHX2 (0.47) | EPHX2DGAT1FAAHGCGRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | EPHX2 1718/4885DGAT1 1/4885FAAH 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.